Table 1 Characteristics of patients
|  | Total N = 279 |
|---|---|
Number of patients (%) | |
Age at diagnosis, median (range years) | 55 (25 – 95) |
Duration of tamoxifen treatment, median (range months) | 21.5 (1 – 70) |
Tamoxifen therapy | Â |
 neoadjuvant | 7 (2.5) |
 adjuvant | 258 (92.5) |
 metastasis | 14 (5) |
Breast cancer treatment | Â |
 surgery | 276 (98.9) |
 received radiation | 148 (53) |
 received chemotherapy | 232 (83.2) |
Hormonal status at diagnosis | Â |
 premenopausal | 81 (29) |
 postmenopausal | 115 (41.2) |
 unknown | 83 (29.7) |
Tumor size | Â |
 T1 | 105 (37.6) |
 T2 | 142 (50.9) |
 T3 | 20 (7.2) |
 T4 | 10 (3.6) |
 unknown | 2 (0.7) |
Node status | Â |
 N 0 | 132 (47.3) |
 N 1 | 112 (40.3) |
 N 2 - 3 | 30 (10.8) |
 unknown | 5 (1.8) |
Differential grade | Â |
 G1 | 39 (14) |
 G2 | 129 (46.2) |
 G3 | 67 (24) |
 unknown | 44 (15.8) |
Histology | Â |
 ductal | 205 (73.5) |
 lobular | 30 (10.8) |
 other | 38 (13.6) |
 unknown | 6 (2.2) |
Hormone receptor status | Â |
 Estrogen+ | 269 (96.4) |
 Progesterone+ | 238 (85.3) |
 Both | 230 (82.4) |
HER2 status | Â |
 positive | 64 (22.9) |
 negative | 210 (75.3) |
 unknown | 5 (1.8) |